Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Flotetuzumab - MacroGenics/Servier

Drug Profile

Flotetuzumab - MacroGenics/Servier

Alternative Names: Anti-CD123/CD3-monoclonal-antibody-MGD006; CD123 x CD3; CD123xCD3-DART-bispecific-antibody-MGD006; CD123xCD3-dual-affinity-re-targeting-bispecific-antibody-MGD006; CD3xCD123-DART-molecule; MGD 006; RES-234; S 80880

Latest Information Update: 14 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MacroGenics
  • Developer MacroGenics; Servier
  • Class Antineoplastics; Bispecific antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia; Myelodysplastic syndromes
  • Preclinical Precursor B-cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 09 Dec 2019 MacroGenics anticipates discussions with the US FDA for flotetuzumab for Acute myeloid leukaemia, in the first half of 2020
  • 09 Dec 2019 MacroGenics plans a registration-enabling study of flotetuzumab for Acute myeloid leukaemia (Refractory metastatic disease, Second-line therapy or greater) ,
  • 07 Dec 2019 Updated efficacy and adverse events data from the phase I trial in Acute myeloid leukaemia presented at the 61st Annual Meeting and Exposition of the American Society of Hematology (ASH-2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top